Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Holding RVNC?
Track your performance easily
RVNC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.30 - $16.98
Previous Close$5.97
Volume5.54M
Average Volume (3M)4.59M
Market Cap
$621.96M
Enterprise Value$881.35M
Total Cash (Recent Filing)$232.24M
Total Debt (Recent Filing)$491.64M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 05, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding104,823,331
10 Day Avg. Volume6,656,316
30 Day Avg. Volume4,589,808
Standard Deviation0.26
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.90
Price to Sales (P/S)2.82
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.61
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda-4.35
Forecast
1Y Price Target
$7.60Price Target Upside27.41% Upside
Rating ConsensusHold
Number of Analyst Covering8
Revance Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market PotentialBoth the skincare and aesthetics markets are gaining significant traction over the years and will continue to grow globally.
Sales PerformanceEncouraging trends behind each product, notably RHA filler strength after the lip filler launch, and Daxxi's accelerating sales (via 2Q24 volume growth of ~65%Y/Y), and the increase in overall aesthetic accounts (now at >8,000) are expected to deliver a strong 2H24.
Strategic MergerThe merger is seen as a strategically positive move for both companies as each has developed complementary products and can together form a more expansive company that now encompasses both aesthetics and skincare.
Bears Say
DebtThe company has $430M in debt and clearly saw a need to find a permanent solution.
Product LaunchRVNC had struggled and significantly underperformed expectations with the launch of Daxxify.
Regulatory RisksRisks include regulatory issues as Daxxi is not FDA-approved for all indications, commercial execution, macroeconomic and consumer spending trends, new competitors in the neurotoxin space, and clinical trial execution in various therapeutic indications.
---
Ownership Overview
12.88% Insiders
37.09% Mutual Funds
48.34% Other Institutional Investors
1.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $2.30 and its highest was $16.98 in the past 12 months.
What is Revance Therapeutics’s market cap?
Currently, no data Available
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Nov 05, 2024 which is in 48 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.288 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.072.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,180,530 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.288 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 19.661%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Perceptive Advisors LLC. It holds Revance Therapeutics’s shares valued at 2M.
---
Revance Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.60 (27.41% Upside)
$7.60 (27.41% Upside)
Blogger Sentiment
Neutral
RVNC Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 397.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.19%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
RVNC Earnings Call
Q2 2024
0:00 / 0:00
---
RVNC Stock 12 Month Forecast
Average Price Target
$7.60
▲(27.41% Upside)
Technical Analysis
Best Analysts Covering RVNC
1 Year
---